CART19 for Pediatric and Young Adult B-ALL
This study is testing a treatment called Murine CART19 for children and young adults (ages 0-29) with certain types of B-cell acute lymphoblastic leukemia (B-ALL). This includes patients with specific genetic changes (hypodiploid or t(17;19) B-ALL), infants with very high-risk KMT2A B-ALL, and those whose cancer has returned in the brain or spinal cord (central nervous system relapse) and who haven't had certain prior treatments. Murine CART19 is a type of cell therapy given by IV injection. The main goal is to see how many patients are free of events (like the cancer coming back) one year after treatment. The study is currently unclear about its recruitment status.
- Study design
- This is an open-label, phase 2 study with four groups of participants. It plans to enroll 133 patients.
- What's involved
- You would need to provide a signed informed consent form. The Murine CART19 treatment is given by IV injection, with a possible reinfusion or retreatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure how long you are free of events for at least one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Orphan Indications for CD19 Redirected Autologous T Cells
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Stephan Grupp, MD, PhD · STUDY_DIRECTOR · Children's Hospital of Philadelphia
- Amanda DiNofia, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital of Philadelphia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Event-free survival (EFS)One year
1 year event-free survival (EFS), where events include no response, relapse, death due to any cause